As healthcare delivery continues to evolve across Canada, Novo Nordisk announces a strategic partnership with Pocketpills, a leading online pharmacy platform, to provide seamless home access to safe and reliable medications including Ozempic® (semaglutide injection) and Wegovy® (semaglutide injection).
The changing healthcare landscape has created unprecedented opportunities for Canadians to manage their health from home. This partnership directly addresses the increasing demand for convenient, stigma-free access to chronic disease treatments, particularly for managing type 2 diabetes and obesity.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.ca, Facebook, Instagram, X, LinkedIn and YouTube.